Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow 
pier article
Related Clinical
Content
space
 arrow  Send comment/rapid response letter
space
 arrow  Published comments/rapid response letters
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box Social Bookmarking
 Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter
What's this?
box PubMed
Articles in PubMed by Author:
 arrow  Palmer, S. C.
space
 arrow  Strippoli, G. F.M.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REVIEW

Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease

right arrow Suetonia C. Palmer, MBChB; David O. McGregor, PhD; Petra Macaskill, PhD; Jonathan C. Craig, PhD; Grahame J. Elder, PhD; and Giovanni F.M. Strippoli, MD, MPH(Hons), MM

18 December 2007 | Volume 147 Issue 12 | Pages 840-853

Background: Vitamin D compounds are widely used to prevent and treat secondary hyperparathyroidism.

Purpose: To determine whether vitamin D therapy improves biochemical markers of mineral metabolism and cardiovascular and mortality outcomes in chronic kidney disease.

Data Sources: MEDLINE (January 1966 to July 2007), EMBASE (January 1980 to July 2007), and Cochrane databases were searched without language restriction.

Study Selection: Randomized, controlled trials of vitamin D compounds in chronic kidney disease were identified.

Data Extraction: Two authors independently extracted data.

Data Synthesis: Seventy-six trials were identified for inclusion; 3667 participants were enrolled. Vitamin D compounds did not reduce the risk for death, bone pain, vascular calcification, or parathyroidectomy. Compared with placebo, established vitamin D sterols were associated with an increased risk for hypercalcemia (relative risk, 2.37 [95% CI, 1.16 to 4.85]) and hyperphosphatemia (relative risk, 1.77 [CI, 1.15 to 2.74]) but did not show a consistent reduction in parathyroid hormone (PTH) levels. Compared with placebo, more recently developed vitamin D analogues were associated with hypercalcemia (relative risk, 5.15 [CI, 1.06 to 24.97]) but not hyperphosphatemia, and levels of PTH were reduced (weighted mean difference, –10.77 pmol/L [CI, –20.51 to –1.03 pmol/L]). For suppression of PTH, intravenous administration was superior to oral vitamin D, but higher intravenous doses were used.

Limitations: Few studies reported patient-level outcomes, including mortality (8 of 76 trials), and only 5 trials directly compared the effects of treatment with newer vitamin D compounds versus established ones. Heterogeneity in some comparisons remained unexplained by metaregression analyses.

Conclusion: Vitamin D compounds do not consistently reduce PTH levels, and beneficial effects on patient-level outcomes are unproven. The value of vitamin D treatment for people with chronic kidney disease remains uncertain.


Editors' Notes
space

Context

  • Clinicians often treat patients with kidney disease with vitamin D compounds to prevent secondary hyperparathyroidism.

Contribution

  • This meta-analysis of 76 randomized trials found no good evidence that vitamin D compounds reduced risk for death, bone pain, vascular calcification, or need for parathyroidectomy in patients with chronic kidney disease. Compared with placebo, established vitamin D sterols increased risk for hypercalcemia and hyperphosphatemia, whereas newer vitamin D analogues increased hypercalcemia but not hyperphosphatemia. Direct comparisons found no clear benefits of newer analogues over established agents.

Implication

  • Though commonly used, vitamin D compounds for chronic kidney disease have unclear benefits and potential harms.

—The Editors

 

Author and Article Information
space

From the Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand; School of Public Health, University of Sydney, and Centre for Transplant and Renal Research, Westmead Millennium Institute, Sydney, Australia; and National Health and Medical Research Council Centre for Clinical Research Excellence in Renal Medicine and The Children's Hospital at Westmead, Westmead, Australia.

Acknowledgment: The authors thank Narelle Willis (Review Group Coordinator of the Cochrane Renal Group), Ruth Mitchell (Trials Search Coordinator of the Cochrane Renal Group), and the Cochrane Renal Group for assistance with preparation of this study.

Financial Support: Partial funding for this project was provided by the Cochrane Renal Group.

Potential Financial Conflicts of Interest: Employment: G.F.M. Strippoli (Diaverum). Consultancies: G.J. Elder (Abbott). Honoraria: G.J Elder (Abbott).

Requests for Single Reprints: Suetonia C. Palmer, MBChB, Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch 8001, New Zealand; or e-mail Dr. Strippoli at strippoli{at}negrisud.it.

Current Author Addresses: Dr. Palmer: Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, 8001, New Zealand.

Dr. McGregor: Department of Nephrology, Christchurch Hospital, Canterbury District Health Board, PO Box 4710, Christchurch, 8001, New Zealand.

Dr. Macaskill: The School of Public Health, Edward Ford Building, The University of Sydney, NSW 2006, Australia.

Dr. Craig: Cochrane Renal Group, Centre for Kidney Research Excellence in Renal Medicine, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.

Dr. Elder: Department of Renal Medicine, Westmead Hospital, Westmead, NSW 2145, Australia.

Dr. Strippoli: Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro (Ch), Italy.

Author Contributions: Conception and design: S.C. Palmer, J.C. Craig, G.F.M. Strippoli.

Analysis and interpretation of the data: S.C. Palmer, G.J. Elder, J.C. Craig, P. Macaskill, G.F.M. Strippoli.

Drafting of the article: S.C. Palmer, G.F.M. Strippoli.

Critical revision of the article for important intellectual content: G.J. Elder, J.C. Craig, D.O. McGregor, G.F.M. Strippoli.

Final approval of the article: S.C. Palmer, G.J. Elder, J.C. Craig, D.O. McGregor, P. Macaskill, G.F.M. Strippoli.

Statistical expertise: P. Macaskill.

Administrative, technical, or logistic support: G.F.M. Strippoli.

Collection and assembly of data: S.C. Palmer, G.F.M. Strippoli.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related articles in Annals:

Editorials
Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun
Marcello Tonelli
Annals 2007 147: 880-881. [Full Text]  

Letters
Vitamin D Compounds in Chronic Kidney Disease
Kenneth Scissors
Annals 2008 148: 969. [Full Text]  

Letters
Vitamin D Compounds in Chronic Kidney Disease
Daniel W. Coyne
Annals 2008 148: 969-970. [Full Text]  

Letters
Vitamin D Compounds in Chronic Kidney Disease
Suetonia C. Palmer, Jonathan C. Craig, AND Giovanni F.M. Strippoli
Annals 2008 148: 970. [Full Text]  



This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
S. C. Palmer, J. C. Craig, and G. F. M. Strippoli
Taking aim at targets
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1358 - 1361.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. G. Vervloet and J. W. R. Twisk
Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 703 - 706.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Tentori, J. M. Albert, E. W. Young, M. J. Blayney, B. M. Robinson, R. L. Pisoni, T. Akiba, R. N. Greenwood, N. Kimata, N. W. Levin, et al.
The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 963 - 972.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
T. B. Drueke and E. Ritz
Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
C. S. Shinaberger, J. D. Kopple, C. P. Kovesdy, C. J. McAllister, D. van Wyck, S. Greenland, and K. Kalantar-Zadeh
Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1769 - 1776.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
S. Fishbane, W. B. Shapiro, D. B. Corry, S. L. Vicks, M. Roppolo, K. Rappaport, X. Ling, W. G. Goodman, S. Turner, and C. Charytan
Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone: The ACHIEVE Study Results
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1718 - 1725.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. L. Regidor, C. P. Kovesdy, R. Mehrotra, M. Rambod, J. Jing, C. J. McAllister, D. Van Wyck, J. D. Kopple, and K. Kalantar-Zadeh
Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients
J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2193 - 2203.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
L. C. Plantinga, N. E. Fink, M. L. Melamed, W. A. Briggs, N. R. Powe, and B. G. Jaar
Serum Phosphate Levels and Risk of Infection in Incident Dialysis Patients
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1398 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Olgaard and E. Lewin
Reply to Dr S.C. Palmer and co-workers
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2709 - 2710.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. B. Shoben, K. D. Rudser, I. H. de Boer, B. Young, and B. Kestenbaum
Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD
J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1613 - 1619.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Alborzi, N. A. Patel, C. Peterson, J. E. Bills, D. M. Bekele, Z. Bunaye, R. P. Light, and R. Agarwal
Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial
Hypertension, August 1, 2008; 52(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
K. Scissors
Vitamin D Compounds in Chronic Kidney Disease
Ann Intern Med, June 17, 2008; 148(12): 969 - 969.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. W. Coyne
Vitamin D Compounds in Chronic Kidney Disease
Ann Intern Med, June 17, 2008; 148(12): 969 - 970.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
P. P. How, D. L. Mason, and A. H. Lau
Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder
Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
K. Olgaard and E. Lewin
Use (or misuse) of vitamin D treatment in CKD and dialysis patients: A recent meta-analysis on vitamin D compounds in chronic kidney disease [1] and an editorial comment [2] accompanying this meta-analysis have already been published. We believe that these papers deserve some comments in the interest of the NDT readership
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1786 - 1789.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Palmer and G. Strippoli
Reply
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2101 - 2102.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
Editorial Note
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1785 - 1785.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Palmer and G. Strippoli
Reply: Vitamin D compounds in chronic kidney disease: change may be needed for good!
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1789 - 1792.
[Full Text] [PDF]


Home page
CJASNHome page
P. Raggi and M. Kleerekoper
Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843.
[Abstract] [Full Text] [PDF]


Home page
JWatch GeneralHome page
Vitamin D Compounds Have Uncertain Benefit in Kidney Disease
Journal Watch (General), January 17, 2008; 2008(117): 1 - 1.
[Full Text]


Home page
BMJHome page
All you need to read in the other general journals
BMJ, January 5, 2008; 336(7634): 16 - 17.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. Tonelli
Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun
Ann Intern Med, December 18, 2007; 147(12): 880 - 881.
[Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Methodological Problems with Vitamin D Meta Analysis
Daniel W Coyne
Annals Online, 15 Jan 2008 [Full text]
Vitamin D in Stage III and IV Chronic Kidney Disease (CKD)
Kenneth N. Scissors
Annals Online, 18 Jan 2008 [Full text]
Vitamin D in chronic kidney disease meta-analysis - Letter in response
Suetonia C Palmer, et al.
Annals Online, 27 Feb 2008 [Full text]



 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2007 by the American College of Physicians.